A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Condition:   SARS-CoV-2 Interventions:   Biological: mRNA-1273;   Biological: Placebo Sponsors:   ModernaTX, Inc.;   Biomedical Advanced Research and Development Authority;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials